SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-260305
Filing Date
2023-10-23
Accepted
2023-10-23 06:31:04
Documents
16
Period of Report
2023-10-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d524225d8k.htm   iXBRL 8-K 31502
2 EX-1.1 d524225dex11.htm EX-1.1 230745
3 EX-4.1 d524225dex41.htm EX-4.1 67984
4 EX-5.1 d524225dex51.htm EX-5.1 9325
8 GRAPHIC g524225g1020194655635.jpg GRAPHIC 2179
  Complete submission text file 0001193125-23-260305.txt   548493

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA rare-20231018.xsd EX-101.SCH 2860
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE rare-20231018_lab.xml EX-101.LAB 17236
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rare-20231018_pre.xml EX-101.PRE 10819
10 EXTRACTED XBRL INSTANCE DOCUMENT d524225d8k_htm.xml XML 3221
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

IRS No.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36276 | Film No.: 231338472
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences